Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of expanded activated lymphocytes after curative resection of high-risk primary hepatocellular carcinoma
CTR20181618Phase 2Active
- Sponsor
- Immunotech Biopharm
- Start
- Sep 2018
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Expanded Activated Lymphocytes in hepatocellular carcinoma (HCC), sponsored by Immunotech Biopharm. Started Sep 2018; status: active.
02
Drugs
Expanded Activated Lymphocytes
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20181618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181618.